加速药物转化:冠状动脉计算机断层扫描血管成像斑块成像候选替代生物标志物的作用
本文综述冠状动脉CTA在冠心病药物研发流程中作为替代生物标志物的潜力,讨论形态学(高危斑块)与定量(特定斑块成分)指标与动脉粥样硬化的病理生理关联、其与主要不良心血管事件的关联证据及对有效药物治疗的反应性,并呼吁影像硬件与软件公司、制药公司、临床医生、患者、监管机构与支付方等关键利益相关方协调合作。
要点
- 冠状动脉CTA可对特定斑块成分进行成像、表征与定量,有望在冠心病药物研发流程中发挥更正式的作用。
- 综述同时评估形态学(高危斑块)与定量(特定斑块成分)两类指标,关注其与主要不良心血管事件的关联证据及对有效药物治疗的反应性。
- 原文指出目前仍缺乏经过稳健验证、能反映动脉粥样硬化本身的心血管事件替代生物标志物。
核心结论
- 冠状动脉CTA已 Emerged 为对特定斑块成分进行成像、表征与定量的理想模态,有望在冠心病药物研发流程中承担更正式的角色。
- 若标准化的冠状动脉CTA终点被验证为临床药物试验的替代终点,该领域进展可能加速创新并提升冠心病药物研发效率。
研究设计与样本
- 本文为综述,评估形态学(高危斑块)与定量(特定斑块成分)两类冠状动脉CTA指标。
- 综述从三方面评价各指标:与其他动脉粥样硬化影像指标的病理生理相关性、各成分与主要不良心血管事件关联的证据、以及对有效药物治疗的反应性。
临床应用与阅片要点
- 原文指出,鉴于冠状动脉CTA采集与分析技术快速进步,亟需影像硬件与软件公司、制药公司、临床医生、患者、监管机构及支付方等关键利益相关方之间协调与合作。
局限性
- 原文指出,迄今仍缺乏经过稳健验证、能反映动脉粥样硬化本身的心血管事件替代生物标志物。
- 原文指出,以主要不良心血管事件作为主要终点虽有利于严谨性,但存在样本量要求大、研究周期长及相关成本与风险等挑战,仍是关键利益相关方的主要顾虑。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
There is an unmet need for new pathways to evaluate therapeutic targets and drugs for coronary artery disease (CAD). The use of major adverse cardiovascular events as a primary outcome is advantageous for rigor, but challenges related to large sample size requirements, long study durations, and associated costs and risks remain major disincentives for key stakeholders. Until now, a robust, well-validated surrogate biomarker for cardiovascular events that reflects atherosclerosis itself has been lacking. This is particularly important as new therapeutic candidates targeting inflammation and factors downstream of low-density lipoprotein and other well-recognized factors continue to emerge. Coronary computed tomography angiography (CTA) has emerged as an ideal modality to image, characterize, and quantify specific plaque components, with potential for a more formal role in the CAD drug development pipeline. This review examines both morphological (high-risk plaque) and quantitative (specific plaque components) measures, considering their pathophysiological correlation with other imaging measures of atherosclerosis, evidence for the association of each component with major adverse cardiovascular events, and their responsiveness to effective drug treatments. Given the rapid advancement in coronary CTA acquisition and analysis technology, there is an urgent need for coordination and collaboration among key stakeholders, including imaging hardware and software companies, pharmaceutical companies, as well as clinicians, patients, regulators, and payers. Progress in this area, and the opportunities that may follow for the broader cardiovascular community if standardized coronary CTA endpoints are validated as surrogates for clinical drug trials, could accelerate innovation and enhance efficiency in CAD drug development.
引用
- Baskaran L, Dutta U, Xiaomeng W, et al. Accelerating Drug Translation: Role of Coronary Computed Tomography Angiography Plaque Imaging Candidates as Surrogate Biomarkers. JACC Cardiovasc Imaging. 2025. PMID: 40769623. doi:10.1016/j.jcmg.2025.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。